These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 26133779)

  • 21. Expression of the human mismatch repair gene hMSH2: a potential marker for urothelial malignancy.
    Leach FS; Hsieh JT; Molberg K; Saboorian MH; McConnell JD; Sagalowsky AI
    Cancer; 2000 May; 88(10):2333-41. PubMed ID: 10820356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective external validation of a bladder cancer detection model.
    Lotan Y; Svatek RS; Krabbe LM; Xylinas E; Klatte T; Shariat SF
    J Urol; 2014 Nov; 192(5):1343-8. PubMed ID: 24859442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis of bladder cancer by urine survivin, an inhibitor of apoptosis: a preliminary report.
    Ziaee SA; Moula SJ; Hosseini Moghaddam SM; Eskandar-Shiri D
    Urol J; 2006; 3(3):150-3. PubMed ID: 17559031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly predictive survival nomogram after upper urinary tract urothelial carcinoma.
    Jeldres C; Sun M; Lughezzani G; Isbarn H; Shariat SF; Widmer H; Graefen M; Montorsi F; Perrotte P; Karakiewicz PI
    Cancer; 2010 Aug; 116(16):3774-84. PubMed ID: 20564085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corrigendum.
    Clin Toxicol (Phila); 2016 Mar; 54(3):295. PubMed ID: 26738544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FGF7 Over Expression is an Independent Prognosticator in Patients with Urothelial Carcinoma of the Upper Urinary Tract and Bladder.
    Fan EW; Li CC; Wu WJ; Huang CN; Li WM; Ke HL; Yeh HC; Wu TF; Liang PI; Ma LJ; Li CF
    J Urol; 2015 Jul; 194(1):223-9. PubMed ID: 25623741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating expression and potential diagnostic and prognostic values of survivin in bladder tumors: a preliminary report.
    Mowla SJ; Emadi Bayegi M; Ziaee SA; Nikpoor P
    Urol J; 2005; 2(3):141-7. PubMed ID: 17602417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erratum.
    Science; 1990 Nov; 250(4985):1195. PubMed ID: 17829190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
    Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
    Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    Urol Oncol; 2007; 25(6):468-75. PubMed ID: 18047954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of CA 125 in transitional cell carcinoma of the bladder.
    Manvar AM; Wallen EM; Pruthi RS; Nielsen ME
    Expert Rev Anticancer Ther; 2010 Dec; 10(12):1877-81. PubMed ID: 21110754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder.
    Xylinas E; Kluth LA; Lotan Y; Daneshmand S; Rieken M; Karakiewicz PI; Shariat SF
    Urol Oncol; 2014 Apr; 32(3):230-42. PubMed ID: 24332648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmented adenovirus transduction of murine T lymphocytes utilizing a bi-specific protein targeting murine interleukin 2 receptor.
    Beatty MS; Timares L; Curiel DT
    Cancer Gene Ther; 2015 Mar; 22(4):222. PubMed ID: 25904493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.
    Karam JA; Lotan Y; Karakiewicz PI; Ashfaq R; Sagalowsky AI; Roehrborn CG; Shariat SF
    Lancet Oncol; 2007 Feb; 8(2):128-36. PubMed ID: 17267327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The current state of NIH funding of research in diagnostic radiology at U.S. medical schools.
    Maguire MA; Gore JC
    J Am Coll Radiol; 2005 May; 2(5):436-43. PubMed ID: 17411851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The National Osteopathic Research Center at the University of North Texas Health Science Center: inception, growth, and future.
    Stoll ST; McCormick J; Degenhardt BF; Hahn MB
    Acad Med; 2009 Jun; 84(6):737-43. PubMed ID: 19474549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CAM evaluation comes into the mainstream: NIH specialized Centers of research and the University of Maryland Center for Alternative Medicine Research in Arthritis.
    Berman BM; Hartnoll S; Bausell B
    Complement Ther Med; 2000 Jun; 8(2):119-22. PubMed ID: 10859605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer.
    Eissa S; Swellam M; Shehata H; El-Khouly IM; El-Zayat T; El-Ahmady O
    J Urol; 2010 Feb; 183(2):493-8. PubMed ID: 20006858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder.
    Nuhn P; May M; Sun M; Fritsche HM; Brookman-May S; Buchner A; Bolenz C; Moritz R; Herrmann E; Burger M; Tilki D; Trojan L; Perrotte P; Haferkamp A; Hohenfellner M; Wieland WF; Müller SC; Karakiewicz PI; Bastian PJ
    Eur Urol; 2012 Jan; 61(1):58-64. PubMed ID: 21840642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.